Poly ADP-Ribose Polymerase (PARP) Inhibitor Industry Insights 2025 – Market Forecast for Executives and Planners
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
#How Has The Poly ADP-Ribose Polymerase (PARP) Inhibitor Market Size Shifted, And What Is the Outlook Through 2034?_x000D_
The market size for the poly ADP-ribose polymerase (PARP) inhibitor has seen substantial growth in the past few years. It’s projected to increase from $8.39 billion in 2024 to $9.41 billion in 2025, with a compound annual growth rate (CAGR) of 12.1%. This significant growth during the historic period can be credited to factors such as clinical research, regulatory approvals, competitive market environment, combined drug usage, and patient advocacy._x000D_
_x000D_
#How Much Will the Poly ADP-Ribose Polymerase (PARP) Inhibitor Market Be Worth in 2029?#_x000D_
The market for the poly ADP-ribose polymerase (PARP) inhibitor is projected to experience significant expansion in the forthcoming years, reaching a value of $14.67 billion in 2029 with a compound annual growth rate (CAGR) of 11.7%. The growth during the forecasted period could be due to factors such as broader applications, individualized treatment plans, development of biomarkers, healthcare economics, and the rise of new markets. Key trends anticipated during this period include precision medicine, advancements in immunotherapy, targeted treatments, the use of artificial intelligence for drug discovery and patient-oriented healthcare._x000D_
_x000D_
#Download The Free Sample Report Here:#_x000D_
https://www.thebusinessresearchcompany.com/sample.aspx?id=15637&type=smp_x000D_
_x000D_
#Which is the Largest Company in the Poly ADP-Ribose Polymerase (PARP) Inhibitor Market?#_x000D_
Major companies operating in the Poly ADP-ribose polymerase (PARP) inhibitor market are Pfizer Inc., Johnson & Johnson Services Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., AstraZeneca plc, GlaxoSmithKline plc., Takeda Pharmaceutical Company Limited, Merck KGaA, Teva Pharmaceutical Industries Ltd., Daiichi Sankyo Company Limited, Eisai Co. Ltd., Ipsen Biopharmaceuticals Inc., Genentech Inc., BioMarin Pharmaceutical Inc., Seattle Genetics Inc., Medivation Inc., Myriad Genetics Inc., PharmaMar S.A., Clovis Oncology, Nektar Therapeutics, Loxo Oncology Inc., Tolero Pharmaceuticals Inc., Everest Pharmaceuticals, Verastem Inc_x000D_
_x000D_
#What Are the Main Market Drivers in the Poly ADP-Ribose Polymerase (PARP) Inhibitor Industry?#_x000D_
The rising incidence of ovarian cancer is anticipated to drive the growth of the poly ADP-ribose polymerase (PARP) inhibitor market. This type of cancer, which results in a malignant tumor in one or both ovaries of a woman — an integral part of the female reproductive system that produces eggs and hormones, is escalating due to factors like genetic predisposition, aging population, environmental factors, and hormonal imbalance. Poly ADP-Ribose Polymerase (PARP) Inhibitors, which target DNA repair mechanisms in patients with BRCA mutations, thus enhancing tumor cell death and leading to synthetic lethality, are used to treat ovarian cancer. As per the World Ovarian Cancer Coalition, a non-profit organization based in Canada, the yearly ovarian cancer mortality rate is expected to rise by almost 70% to 350,956 by 2024. Therefore, the escalating rate of ovarian cancer worldwide is fuelling the growth of the poly ADP-ribose polymerase (PARP) inhibitor market._x000D_
_x000D_
#Request For A Customized Report:#_x000D_
https://www.thebusinessresearchcompany.com/customise?id=15637&type=smp_x000D_
_x000D_
#How Is the Poly ADP-Ribose Polymerase (PARP) Inhibitor Market Segments Structured?#_x000D_
The poly ADP-ribose polymerase (PARP) inhibitor market covered in this report is segmented –_x000D_
_x000D_
1) By Drug Type: Talazoparib, Veliparib, Olaparib, Other Drug Types_x000D_
2) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy, Other Distribution Channels_x000D_
3) By Application: Ovarian Cancer, Breast Cancer, Other Applications_x000D_
4) By End Users: Hospitals, Homecare, Specialty Clinics, Other End Users_x000D_
_x000D_
Subsegments:_x000D_
1) By Talazoparib: Talazoparib For Breast Cancer, Talazoparib For Ovarian Cancer, Talazoparib For Prostate Cancer, Talazoparib For Other Cancers_x000D_
2) By Veliparib: Veliparib For Breast Cancer, Veliparib For Ovarian Cancer, Veliparib For Non-Small Cell Lung Cancer (Nsclc), Veliparib For Other Cancers_x000D_
3) By Olaparib: Olaparib For Breast Cancer (Her2-negative), Olaparib For Ovarian Cancer (Brca-mutated), Olaparib For Prostate Cancer (Brca-Mutated), Olaparib For Pancreatic Cancer (Brca-Mutated), Olaparib For Other Cancers_x000D_
4) By Other Drug Types: Niraparib, Rucaparib, Pembrolizumab (Combination Therapy With Parp Inhibitors), Other Parp Inhibitors (Emerging Drugs In Clinical Trials)_x000D_
_x000D_
#What Strategic Trends Are Transforming the Poly ADP-Ribose Polymerase (PARP) Inhibitor Market?#_x000D_
Major firms in the Poly ADP-Ribose Polymerase (PARP) inhibitor market are focusing on creating generic PARP inhibitors, aimed at providing customized treatment strategies for cancer patients carrying specific genetic mutations. These inhibitors are medications that obstruct the functions of the poly ADP-ribose polymerase (PARP) enzyme. Zydus Lifesciences Limited, an Indian pharmaceutical company, for instance, introduced a PARP inhibitor called Olaparib under the brand name IBYRA in March 2024. Their goal was to improve the provision of cutting-edge cancer treatment. IBYRA is specifically designed to target genetic mutations present in breast, ovarian, prostate, and pancreatic cancers, thereby providing an efficient and personalized treatment plan. The medication is especially useful for patients with HRD-positive or BRACA mutations, as it helps slow down the progression of the disease._x000D_
_x000D_
#Access The Full Report Here:#_x000D_
_x000D_
#Which Global Regions Offer the Highest Growth in the Poly ADP-Ribose Polymerase (PARP) Inhibitor Market?#_x000D_
North America was the largest region in the poly ADP-ribose polymerase (PARP) inhibitor market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the Poly ADP-ribose polymerase (PARP) inhibitor market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_
_x000D_
#Purchase The Full Report Today:#_x000D_
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15637_x000D_
_x000D_
#This Report Delivers Insight On: #_x000D_
1. How big is the poly adp-ribose polymerase (parp) inhibitor market, and how is it changing globally?_x000D_
2. Who are the major companies in the poly adp-ribose polymerase (parp) inhibitor market, and how are they performing?_x000D_
3. What are the key opportunities and risks in the poly adp-ribose polymerase (parp) inhibitor market right now?_x000D_
4. Which products or customer segments are growing the most in the poly adp-ribose polymerase (parp) inhibitor market?_x000D_
5. What factors are helping or slowing down the growth of the poly adp-ribose polymerase (parp) inhibitor market?_x000D_
_x000D_
#About The Business Research Company:#_x000D_
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_
_x000D_
#Get in touch with us:#_x000D_
The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_
Americas +1 310-496-7795_x000D_
Asia +44 2071930708_x000D_
Europe +44 7882 955267_x000D_
Email us at info@tbrc.info_x000D_
_x000D_
#Follow us on:#_x000D_
_x000D_
LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
